甲状腺炎：enasidenib诱导分化综合征的一种罕见表现。
Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome.
作者信息
Annamaraju Pavan, Gopishetty Swathi, Goparaju Naga, Beasey Matthew, Kota Vamsi, Guddati Achuta K
机构信息
Johnston Memorial Hospital, Ballad Health System, Abingdon, Virginia, USA.
Medical Center of Central Georgia, Mercer University, Macon, Georgia, USA.
出版信息
Case Rep Oncol. 2020 May 27;13(2):583-587. doi: 10.1159/000507613. eCollection 2020 May-Aug.
Enasidenib is an FDA-approved isocitrate dehydrogenase 2 (IDH2) inhibitor, which is used in the treatment of acute myeloid leukemia (AML). We present a case of AML with an IDH2 mutation treated with a regimen of enasidenib and 5-azacitidine, where thyroiditis was noted to be a part of differentiation syndrome. The patient is a 77-year-old woman with IDH2-mutated AML who had initially been started on 100 mg of enasidenib and then presented with dyspnea and was diagnosed with pleural effusion - a common presentation with enasidenib - but was also noted to have thyroiditis. She was started on steroids, but due to continued hyperbilirubinemia and thyroiditis, her dose of enasidenib was reduced to half, which resulted in clinical improvement. This case demonstrates thyroiditis as one of the rare manifestations in the treatment of AML with enasidenib-induced differentiation syndrome.
恩杂鲁胺是一种经美国食品药品监督管理局（FDA）批准的异柠檬酸脱氢酶2（IDH2）抑制剂，用于治疗急性髓系白血病（AML）。我们报告了1例IDH2突变的AML患者，采用恩杂鲁胺和5-阿扎胞苷方案治疗，其中甲状腺炎被认为是分化综合征的一部分。该患者为一名77岁女性，患有IDH2突变的AML，最初开始服用100mg恩杂鲁胺，随后出现呼吸困难，被诊断为胸腔积液——恩杂鲁胺的常见表现——但也被发现患有甲状腺炎。她开始使用类固醇治疗，但由于持续的高胆红素血症和甲状腺炎，她的恩杂鲁胺剂量减半，这导致了临床症状改善。该病例表明，甲状腺炎是恩杂鲁胺诱导的分化综合征治疗AML中罕见的表现之一。
Zotero 插件